Literature DB >> 24426712

Molecular biology of lung cancer-a review.

Dinesh Pendharkar1, B V Ausekar2, Sumant Gupta3.   

Abstract

Lung cancer is leading site of cancer in Indian males today. The incidence is on the rise. It is generally diagnosed in late stages. The progression free survival and overall survival still remains low. Majority of oncology research today is driven towards molecular profiling of lung cancer. Receptor tyrosine kinases have emerged as major molecular markers and targets. These are the results of gene mutations or amplifications. There are many developed targets where therapeutic option is available like EGFR, ALK, MET, KRAS and so on. This review features on few important molecular profiles of lung cancer, especially with more therapeutic implications.

Entities:  

Keywords:  ALK; EGFR; Lung cancer; NSCLC

Year:  2013        PMID: 24426712      PMCID: PMC3693139          DOI: 10.1007/s13193-013-0213-3

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  15 in total

1.  EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.

Authors:  Jussi P Koivunen; Craig Mermel; Kreshnik Zejnullahu; Carly Murphy; Eugene Lifshits; Alison J Holmes; Hwan Geun Choi; Jhingook Kim; Derek Chiang; Roman Thomas; Jinseon Lee; William G Richards; David J Sugarbaker; Christopher Ducko; Neal Lindeman; J Paul Marcoux; Jeffrey A Engelman; Nathanael S Gray; Charles Lee; Matthew Meyerson; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

2.  Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.

Authors:  Paul K Paik; Maria E Arcila; Michael Fara; Camelia S Sima; Vincent A Miller; Mark G Kris; Marc Ladanyi; Gregory J Riely
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

Review 3.  Hyperactive Ras in developmental disorders and cancer.

Authors:  Suzanne Schubbert; Kevin Shannon; Gideon Bollag
Journal:  Nat Rev Cancer       Date:  2007-04       Impact factor: 60.716

4.  Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells.

Authors:  L Xu; M B Nilsson; P Saintigny; T Cascone; M H Herynk; Z Du; P G Nikolinakos; Y Yang; L Prudkin; D Liu; J J Lee; F M Johnson; K-K Wong; L Girard; A F Gazdar; J D Minna; J M Kurie; I I Wistuba; J V Heymach
Journal:  Oncogene       Date:  2010-02-15       Impact factor: 9.867

5.  The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.

Authors:  Daisy Wing-Sze Wong; Elaine Lai-Han Leung; Kimpton Kam-Ting So; Issan Yee-San Tam; Alan Dart-Loon Sihoe; Lik-Cheung Cheng; Kwok-Keung Ho; Joseph Siu-Kie Au; Lap-Ping Chung; Maria Pik Wong
Journal:  Cancer       Date:  2009-04-15       Impact factor: 6.860

6.  Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.

Authors:  Rafael Rosell; Kathleen D Danenberg; Vincente Alberola; Gerold Bepler; Jose Javier Sanchez; Carlos Camps; Mariano Provencio; Dolores Isla; Miquel Taron; Pilar Diz; Angel Artal
Journal:  Clin Cancer Res       Date:  2004-02-15       Impact factor: 12.531

7.  Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.

Authors:  Young Lim Choi; Kengo Takeuchi; Manabu Soda; Kentaro Inamura; Yuki Togashi; Satoko Hatano; Munehiro Enomoto; Toru Hamada; Hidenori Haruta; Hideki Watanabe; Kentaro Kurashina; Hisashi Hatanaka; Toshihide Ueno; Shuji Takada; Yoshihiro Yamashita; Yukihiko Sugiyama; Yuichi Ishikawa; Hiroyuki Mano
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

Review 8.  KRAS mutations in non-small cell lung cancer.

Authors:  Gregory J Riely; Jenifer Marks; William Pao
Journal:  Proc Am Thorac Soc       Date:  2009-04-15

9.  AKT1(E17K) in human solid tumours.

Authors:  F E Bleeker; L Felicioni; F Buttitta; S Lamba; L Cardone; M Rodolfo; A Scarpa; S Leenstra; M Frattini; M Barbareschi; M Del Grammastro; M G Sciarrotta; C Zanon; A Marchetti; A Bardelli
Journal:  Oncogene       Date:  2008-05-26       Impact factor: 9.867

10.  Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

Authors:  Klarisa Rikova; Ailan Guo; Qingfu Zeng; Anthony Possemato; Jian Yu; Herbert Haack; Julie Nardone; Kimberly Lee; Cynthia Reeves; Yu Li; Yerong Hu; Zhiping Tan; Matthew Stokes; Laura Sullivan; Jeffrey Mitchell; Randy Wetzel; Joan Macneill; Jian Min Ren; Jin Yuan; Corey E Bakalarski; Judit Villen; Jon M Kornhauser; Bradley Smith; Daiqiang Li; Xinmin Zhou; Steven P Gygi; Ting-Lei Gu; Roberto D Polakiewicz; John Rush; Michael J Comb
Journal:  Cell       Date:  2007-12-14       Impact factor: 41.582

View more
  6 in total

Review 1.  BRAF mutations in patients with non-small cell lung cancer: a systematic review and meta-analysis.

Authors:  Dong Chen; Li-Qun Zhang; Jun-Fu Huang; Kai Liu; Zheng-Ran Chuai; Zhao Yang; Yun-Xia Wang; Da-Chuan Shi; Qian Liu; Qing Huang; Wei-Ling Fu
Journal:  PLoS One       Date:  2014-06-30       Impact factor: 3.240

2.  A meta-analysis of the association between BRAF mutation and nonsmall cell lung cancer.

Authors:  Guanghui Cui; Donglei Liu; Weihao Li; Xiao Fu; Youguang Liang; Yuhang Li; Wensong Shi; Xiaofang Chen; Song Zhao
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

3.  Predominance of the Rare EGFR Mutation p.L861Q in Tunisian Patients with Non-Small Cell Lung Carcinoma.

Authors:  Rania Abdelmaksoud-Dammak; Nihel Ammous-Boukhris; Amèna Saadallah-Kallel; Slim Charfi; Souhir Khemiri; Rim Khemakhem; Nesrin Kallel; Wala Ben Kridis-Rejeb; Tahya Sallemi-Boudawara; Afef Khanfir; Ilhem Yangui; Jamel Daoud; Raja Mokdad-Gargouri
Journal:  Genes (Basel)       Date:  2022-08-22       Impact factor: 4.141

4.  XRCC3 Thr241Met Polymorphism is not Associated with Lung Cancer Risk in a Romanian Population.

Authors:  Andreea Catana; Monica Pop; Dragos Horea Marginean; Ioana Cristina Blaga; Mihai Dumitru Porojan; Radu Anghel Popp; Ioan Victor Pop
Journal:  Clujul Med       Date:  2016-01-15

5.  Identification of a Novel BRAF Thr599dup Mutation in Lung Adenocarcinoma.

Authors:  Xuefei Zhang; Mo Li; Desheng Lv; Ge Sun; Yu Bai; Hui Tian; Changhong Liu
Journal:  Open Med (Wars)       Date:  2018-07-10

6.  Research Progress and Applications of Multivalent, Multispecific and Modified Nanobodies for Disease Treatment.

Authors:  Jiewen Wang; Guangbo Kang; Haibin Yuan; Xiaocang Cao; He Huang; Ario de Marco
Journal:  Front Immunol       Date:  2022-01-18       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.